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Abstract
Background: Aortic valve (AV) calcification preferentially occurs on the fibrosa side while the ventricularis side remains
relatively unaffected. Here, we tested the hypothesis that side-dependent activation of bone morphogenic protein (BMP)
pathway in the endothelium of the ventricularis and fibrosa is associated with human AV calcification.
Methods and Results: Human calcified AVs obtained from AV replacement surgeries and non-calcified AVs from heart
transplantations were used for immunohistochemical studies. We found SMAD-1/5/8 phosphorylation (a canonical BMP
pathway) was higher in the calcified fibrosa than the non-calcified fibrosa while SMAD-2/3 phosphorylation (a canonical
TGFb pathway) did not show any difference. Interestingly, we found that BMP-2/4/6 expression was significantly higher on
the ventricularis endothelium compared to the fibrosa in both calcified and non-calcified AV cusps; however, BMP
antagonists (crossvienless-2/BMPER and noggin) expression was significantly higher on the ventricularis endothelium
compared to the fibrosa in both disease states. Moreover, significant expression of inhibitory SMAD-6 expression was found
only in the non-calcified ventricularis endothelium.
Conclusions: SMAD-1/5/8 is preferentially activated in the calcified fibrosa endothelium of human AVs and it correlates with
low expression of BMP antagonists and inhibitory SMAD6. These results suggest a dominant role of BMP antagonists in the
side-dependent calcification of human AVs.
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Introduction
Aortic valve (AV) disease is a major cause of cardiac deaths
worldwide and is a strong risk factor for additional cardiovascular
events [1,2,3]. With the aging United States population, it is
believed that 20% of individuals over the age of 80 have AV
calcification, making it the most common cardiac disease [4]. AV
calcification was once thought to be a passive degenerative disease
but is now known as an active inflammatory pathology [5,6,7]. AV
calcification is characterized by the accumulation of calcium,
inorganic phosphates, extracellular matrix proteins, bone-related
factors [8,9,10], and osteoblast-like cells [8,11] in the fibrosa, or
aortic side, of the valve cusp [10,12].
The AV is comprised of three distinct layers: the fibrosa, ven-
tricularis, and spongiosia. The fibrosa, which faces the aorta, is
comprised of collagen fibers, while the ventricularis faces the left
ventricle and is comprised of elastin and collagen fibers. Finally, the
spongiosia,which is located inbetween thefibrosaand ventricularis,
is comprised of glycosaminoglycans [13]. A continuous endothelial
monolayer covers the valve, while a healthy valvular leaflet contains
a heterogeneous population of valvular interstitial cells [13]. The
AVresidesina complexmechanical environmentthatincludesfluid
shear stresses, varying pressures, and bending stresses [14]. Similar
to the vascular endothelial system, where atherosclerosis preferen-
tially occurs in areas of disturbed flow, AV calcificationand sclerosis
primarily occur in a side-dependent manner [15,16,17,18,19]. The
fibrosa endothelium experiences disturbed flow conditions through-
out the cardiac cycle and is prone to accelerated AV calcification.
Conversely, the ventricularis endothelium experiences stable flow
during systole and remains relatively unaffected. The correlation
between hemodynamic forcesandAV diseasedevelopmentsuggests
that the AV endothelium may be playing a role in AV disease
development. Recent studies performed by our group and others
have begun to investigate the endothelium’s role in AV valve
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endothelium of porcine AVs, Simmons et al. found the pro-
inflammatory and bone growth chemokine bone morphogenic
protein 4 (BMP-4) was expressed on the fibrosa endothelium, while
chordin, a natural BMP antagonist, was found to be up-regulated
on the ventricularis endothelium. This suggests a pro- and anti-
osteogenic conditions on the fibrosa and ventricularis sides respec-
tively [20]. Butcher, et al. found that porcine AV endothelial cells,
when exposed to unidirectional laminar flow, decreased BMP-4
expression [15]. Furthermore, BMP-4 expression was higher in the
fibrosa of porcine AV compared to the ventricularis (14). It was also
reported that BMPs -2 and -4 are present in calcified regions of
human AV [21]. However, it is not known whether BMPs are
activated in endothelial cells in a side-dependent manner and
whether it correlates with calcification in human AVs.
BMPs are members of the TGFb superfamily. Initially dis-
covered as inducers of bone formation [8], the BMPs are now
known to play important roles in embryonic development, patter-
ning, cartilage formation, and cell differentiation [22,23]. We have
shown that BMP-4 is a mechanosensitive and proinflammatory
cytokine in vascular endothelial cells [24,25]. Furthermore, BMP-
4 infusion induced hypertension in mice in a NADPH oxidase-
dependent manner [26]. In addition, BMP-2 and -4 expression is
increased in calcified human AVs and human atherosclerotic
lesions [21,27].
Another classification of molecules, BMP antagonists, bind to
the BMPs with varying degrees of affinity. Once bound, BMP
antagonists inhibit the interaction of the BMPs with their cognate
receptors [28,29,30,31,32,33]. BMP antagonists include, noggin,
crossveinless 2 (CV-2, also known as BMPER), chordin, follistatin,
DAN and matrix Gla protein-1(MGP-1) [34]. In porcine AV
leaflets, chordin was increased on the ventricularis endothelium
[20]. Interestingly, uncarboxylated MGP-1 is decreased in the
plasma of human patients that have AV calcification versus the
healthy cohort [35].
The BMPs and TGFb have two types of specific signaling
receptors: BMPR-I and BMPR-II, or TGFbR-1 and TGFbR-II,
respectively, and both are required for signaling. Once the ligand
is bound to its receptors, the active domain of the type II receptor
phosphorylates the type I receptor, which in turn phosphorylates
the R-SMADs (phospho-SMAD 1, 2, 3, 5, 8) [36,37]. SMAD-2/3
and SMAD-1/5/8 are canonical mediators of TGFb and BMP
signaling, respectively. These phospho-SMADs then bind with co-
SMAD-4 and translocate into the nucleus, regulating a wide range
of gene expression. SMAD-6, an inhibitory SMAD, can block the
R-SMADs from being phosphorylated by competing for activation
of the type I receptors [36,37].
Table 1. Patient Characteristics.
Calcified Non-Calcified
Number of Patients 16 6
Age (mean 6 SD) 66.4616.28 54.768.5
Female 7 (43.8%) 1 (16%)
Bicuspid valves 1 (6.25%) 0 (0%)
Ejection Fraction (mean 6 SD) 0.49860.139 NA
NYHA* (mean 6 SD) 2.261.1 NA
Congestive Heart Failure 9 (56.25%) 6 (100%)
Diabetes mellitus 2 (12.5%) 3 (50%)
Hemoglobin A1C (mean 6 SD) 661.18 NA
Dyslipidemia 6 (37.5%) NA
Hypertension 12 (75%) 2 (33.3%)
Last Creatinine Level (mean 6 SD) 1.1260.33 NA
Dialysis 0 (0%) NA
*NYHA - New York Heart Association.
doi:10.1371/journal.pone.0020969.t001
Figure 1. Calcification and endothelial staining of AV cusps.
Valves were obtained from either heart transplant (non-calcified) or
valve replacement (calcified) surgeries, snap frozen and sectioned.
Sections were then stained for H&E (A, E), alizarin red (B, F), Verhoeff
Van Giessen (C, G) or von Willebrand factor (D, H). Representative
staining (n=12 patients) shows side-specific calcification (*) in calcified
leaflets (B, F), while maintaining an intact endothelial layer
(D, H: arrows). Verhoeff Van Giessen stain was used to stain for elastin
(shown in black, arrows) to help in leaflet orientation (C, G). f: fibrosa,
v: ventricularis.
doi:10.1371/journal.pone.0020969.g001
Activation of SMAD1/5/8 on the Fibrosa Endothelium
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play a role in human AV calcification. We hypothesized that BMP
pathway is preferentially activated in the fibrosa endothelium,
which leads to side-specific human AV calcification in the fibrosa.
Our current study using calcified and non-calcified human AVs
show that phospho-SMAD-1/5/8 is significantly higher in the
fibrosa endothelium, suggesting that BMP pathway is preferen-
tially activated in the fibrosa endothelium of calcified human AVs.
Our studies further show that the fibrosa-dependent activation of
the BMP pathway correlates well with decreased levels of BMP
antagonists and inhibitory SMAD-6.
Materials and Methods
Human AV Procurement
AVs were received from two patient populations according
to the IRB-approved study at Emory University with written
informed consent. Calcified human AVs were obtained immedi-
ately following valve replacement surgeries in 16 patients at Emory
University Hospital Midtown. Fifteen patients had trileaflet valves,
while one patient had a bicuspid AV. Non-calcified AV (n=6, all
trileaflet AV) were harvested from recipient patients undergoing
heart transplantation at Emory University Hospital. Two of the
six patients underwent cardiac transplantation due to ischemic
cardiomyopathy. Patient demographics are presented in Table 1.
Immediately following harvesting, the AVs were photographed,
washed in ice-cold phosphate buffered saline, and cusps were
individually snap-frozen in optimal cutting temperature (O.C.T.)
compound (Tissue-Tek). Valves were then sectioned (7 mm) in the
radial direction to include the base and free edge (tip), stored at
280uC and used for immunohistochemical staining studies.
Histochemistry and Immunohistochemistry
Hematoxalin and eosin (H&E for general histology), Verhoeff
Van Giessen (for elastin), and Alizarin Red (for calcification)
staining was carried out for histomorphometric analysis. Immu-
nohistochemical studies were carried out as previously described
[34] using the following specific antibodies: endothelial marker;
Figure 2. Phospho-SMAD 1/5/8 level is high in calcified fibrosa endothelium. Calcified and non-calcified AV sections were stained for
phospho-SMAD 1/5/8 (A–F), and phospho-SMAD 2 (H–M), and a rhodamine-labeled secondary antibody. Shown are representative images. Bar
graphs show staining intensities of fibrosa- and ventricularis-endothelium for each SMAD (G, N) (mean+SEM). For phospho-SMAD 1/5/8, n=13
calcified and n=12 non-calcified. For phospho-SMAD 2, n=14 calcified and n=13 non-calcified. For SMAD-6, n=22 calcified and n=15 non-calcified.
*p,0.05, #p,0.06. f: fibrosa, v: ventricularis.
doi:10.1371/journal.pone.0020969.g002
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(Lifespan Biosciences, 1:100), BMP-4 (Biovision, 1:25), and BMP-6
(Santa Cruz. 1:25), BMP antagonists; noggin (LabFrontier, 1:100),
CV-2/BMPER (R&D, 1:100), MGP-1 (ABCAM, 1:100) and DAN
(R&D, 1:25), phospho-SMAD-1/5/8 (Cell Signaling, 1:200) and
phospho-SMAD-2 (Cell Signaling, 1:100), and SMAD-6 (Lifespan
Biosciences 1:25). Rhodamine Red X antibody (Jackson Labs) was
used as a secondary antibody with a Hoechst dye nuclear counter
staining. Fluorescent images were taken with a Zeiss Axioskop
epifluorescence microscope using a 106objective.
Image Analysis
Three cross-sectional images were obtained from each AV
section, where endothelial layer staining was present based on
Hoechst staining. Digital images were then graded for endothelial
staining intensity from 0 (no positive staining) to 5 (most intense
positive staining) by three blinded individuals. The grades of the
three cross-sections were averaged to determine the staining
intensity of each antibody examined. The fibrosa and ventricularis
endothelium were graded separately.
Statistical Analysis
All data are reported by mean 6 SE with n signifying the
number of different AV leaflets stained. Significant differences
were determined by ANOVA using a Tukey HSD testing. All
p-values,0.05 were considered significant.
Results
Immunohistochemical examination of AVs
H&E staining for general histology (Figure 1A,E), Alizarin Red
(Figure 1B,F) for calcification and Verhoeff Van Giessen
(Figure 1C,G) for elastin was carried out with calcified and non-
calcified human AVs (Table 1). All human AVs (n=6 patients)
obtained from the heart transplantation patients were negative for
Alizarin Red staining (Fig. 1F), suggesting that they were not
calcified. In contrast, all calcified AVs (n=16 patients) obtained
from AV replacement surgeries were confirmed by Alizarin Red
staining (Figure 1B). To examine the presence of an intact
endothelium, von Willebrand factor staining was performed on the
AV leaflet (Figure 1D, H). Intact endothelium was confirmed on
valves used in our study.
Preferential activation of BMP-dependent SMAD1/58
pathway in calcified human AV
To determine whether the BMP pathway is activated in human
AV endothelium in a side- dependent manner, we examined the
level of phospho-SMAD-1/5/8, a canonical BMP activation
pathway marker. Intense phospho-SMAD-1/5/8 staining was
observed only in the calcified fibrosa endothelium (Fig. 2A–G). In
contrast, non-calcified AV endothelium in both fibrosa and
ventricularis showed only faint levels of phospho-SMAD-1/5/8.
While the phospho-SMAD-1/5/8 staining level was low in the
calcified ventricularis, it did not reach statistical significance in
comparison to the calcified fibrosa (Fig. 2G).
As a comparison, phospho-SMAD-2 levels, a canonical TGFb
signaling activation marker, was studied. Overall, we did not
observe any statistically significant differences in phospho-SMAD-
2 levels in any of the AV endothelial groups; however, we found a
trend for lower phospho-SMAD-2 levels in the non-calcified
fibrosa endothelium (p,0.1, n=13) compared to the non-calcified
ventricularis endothelium (Fig. 2 H–N).
Side-dependent expression of BMPs in human AV
Next, we determined whether the side- and calcification-
dependent phosphorylation of SMAD-1/5/8 correlates with
BMP expression levels. Robust expression of BMPs -2, -4, and
-6 was observed in all the tested AV endothelium. To our surprise,
based on previous studies using healthy porcine AVs [15,20],
BMP-2, -4, and -6 expression was higher in ventricularis endo-
thelium than fibrosa endothelium (Figure 3). BMP-2 and -4
expression was significantly higher in non-calcified ventricularis
endothelium compared to the fibrosa endothelium of both cal-
cified and non-calcified AVs (Figure 3 A–N). BMP-6 expression
was significantly higher in the calcified ventricularis endothelium
than the fibrosa endothelium (Figure 3 O–U). There was no
significant difference in expression levels of all three BMPs in the
ventricularis endothelium of calcified and non-calcified AVs. The
same was true for the fibrosa endothelium of calcified and non-
calcified AVs (Figure 3).
Side-dependent expression of BMP antagonists and the
inhibitory SMAD-6 in human AV
Next, we determined whether the side- and calcification-
dependent phosphorylation of SMAD-1/5/8 correlates with expre-
ssion levels of BMP antagonists (CV-2/BMPER, noggin, DAN,
follistatin, chordin, and MGP-1). CV-2/BMPER and noggin
expression was significantly lower in the fibrosa endothelium both
in calcified and non-calcified AVs (Figure 4 A–G). Furthermore, we
found that CV-2/BMPER expression was significantly reduced in
the calcified ventricularis endothelium than the non-calcified
ventricularis endothelium (Figure 4G), while this disease-depen-
dency was not observed for noggin (Figure 4N). DAN expression
was not significantly different in the endothelium; although, a trend
of decreased staining was seen between the calcified and non-
calcified fibrosa endothelium (Figure 4H–N). At this time, none
of the available antibodies that we examined resulted in specific
staining patterns for follistatin, chordin, and MGP-1, when com-
pared to isotype IgG controls (data not shown). Lastly, we examined
the level of inhibitory SMAD-6. SMAD-6 expression was signi-
ficantly higher in non-calcified ventricularis endothelium compared
to non-calcified fibrosa endothelium and endothelium of calcified
valves (Figure 5G).
Discussion
The main findings of our current work are that 1) phosphory-
lation of SMAD-1/5/8 is significantly increased in calcified fibrosa
endothelium,2)surprisingly,BMP-2/4/6 expression ishigherinthe
ventricularisendotheliuminbothcalcified andnon-calcifiedAVs, 3)
BMP antagonists noggin and CV2/BMPER expression was in-
creased in the ventricularis endothelium in both calcified and non-
calcified AVs, and 4) inhibitory SMAD-6 expression was highest in
the non-calcified ventricularis endothelium. These results suggest
that the side-dependent calcification of human AV is linked to the
Figure 3. BMP expression in the fibrosa and ventricularis endothelium. Calcified and non-calcified AV sections were stained for BMP-2
(A–F), BMP-4 (H–M), and BMP-6 (O–T), and a rhodamine-labeled secondary antibody. Shown are representative images. Bar graphs show staining
intensities of fibrosa- and ventricularis-endothelium for each BMP (G, N, U) (mean+SEM). For BMP-2, n=13 calcified and n=13 non-calcified. For BMP-
4, n=9 calcified and n=8 non-calcified. For BMP-6, n=12 calcified and n=11 non-calcified. *p,0.05. f: fibrosa, v: ventricularis.
doi:10.1371/journal.pone.0020969.g003
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SMAD-1/5/8 activation in the fibrosa endothelium correlates with
the decreased levels of the BMP antagonists (noggin and CV-2/
BMPER) and inhibitory SMAD-6.
AV calcification and sclerosis primarily occur in the fibrosa,
while the ventricularis is relatively unaffected [10,12]; however,
the specific mechanisms underlying this side-dependent AV disease
is unclear. Our initial hypothesis was that the side-dependent AV
calcification is mediated by preferential activation of BMP signa-
ling pathway in the fibrosa endothelium. To test this hypothesis,
we studied SMAD-1/5/8 phosphorylation, the canonical BMP
pathwayactivationmarker,bystainingfrozensectionsofAVleaflets
obtained from patients undergoing AV replacement (calcified AVs)
or heart transplantation(non-calcifiedAVs) surgeries (Table 1).Our
results showedthat SMAD-1/5/8 waspreferentially activatedinthe
calcified fibrosa endothelium compared to non-calcified fibrosa
endothelium (Fig. 2). In contrast, we found no significant differences
inphospho-SMAD-2levelsamongallgroups(Fig.2),indicatingthat
there was no differential activation of the canonical TGFb signaling
pathway in human AV endothelium. These findings demonstrate a
strong correlation between the phospho-SMAD-1/5/8 activationin
the endothelium and calcification in the fibrosa side in human AVs.
Previous results have shown clear evidence that disturbed flow
stimulates BMP-4 expression in endothelial cells in vitro, ex vivo and
in vivo, and that BMP expression leads to endothelial inflammation,
aortic wall calcification and AV calcification [21,24,25,27,38]. In
addition, in normal pig AVs, BMP-4 mRNA and protein levels are
higher on fibrosa endothelium [15,20], further demonstrating the
close correlation among disturbed flow, BMP-4 expression in the
fibrosa endothelium, and side-specific AV calcification.
Therefore, we next tested the hypothesis that the preferential
activation of SMAD-1/5/8 on the fibrosa endothelium is medi-
ated by increased BMP expression due to disturbed flow condi-
tions. Contrary to our hypothesis, however, we found that BMP-
2,-4 and -6 expression was higher on the ventricularis endothelium
compared to fibrosa endothelium of both calcified and non-
calcified AV (Figure 3). These results show, unlike in normal
healthy porcine AVs, that endothelial BMP expression levels
in both calcified and non-calcified human AVs do not correlate
with the side-dependent AV calcification and phosphorylation of
SMAD-1/5/8. It is interesting, however, that a recent study
showed that BMP-4 levels were decreased in the fibrosa endo-
thelium of the hypercholesterolemic pig AVs compared to the
normal pig AV [19]. This surprising result in diseased pigs is
consistent with our current finding in diseased human AVs.
We next tested the alternative hypothesis that decreased expre-
ssion of BMP antagonists in the fibrosa endothelium is responsible
for the preferential activation of SMAD-1/5/8 and calcification in
human AVs. Our results show that noggin and CV-2/BMPER
expression levels were higher in the ventricularis endothelium than
the fibrosa endothelium in both calcified and non-calcified AVs.
These results suggest that abundant levels of BMPantagonists in the
ventricularis endothelium, especially in non-calcified human AVs,
provide an anti-calcific environment. These results are also con-
Figure 4. BMP antagonist expression in the fibrosa and ventricularis endothelium. Calcified and non-calcified AV sections were stained for
CV-2/BMPER (A–F), noggin (H–M), DAN (O–T), and SMAD-6 (V–BB), and a rhodamine-labeled secondary antibody. Shown are representative images.
Bar graphs show staining intensities of fibrosa- and ventricularis-endothelium for each antagonist (G, N, U, BB) (mean+SEM). For CV-2/BMPER, n=20
calcified and n=14 non-calcified. For noggin, n=14 calcified and n=6 non-calcified. For DAN, n=10 calcified and n=8 non-calcified. For SMAD-6,
n=22 calcified and n=15 non-calcified. *p,0.05, f: fibrosa, v: ventricularis.
doi:10.1371/journal.pone.0020969.g004
Figure 5. SMAD-6 expression in the fibrosa and ventricularis endothelium. Calcified and non-calcified AV sections were stained for SMAD-6,
and a rhodamine-labeled secondary antibody. Shown are representative images. Bar graphs show staining intensities of fibrosa- and ventricularis-
endothelium for each antagonist (G) (mean+SEM). For SMAD-6, n=22 calcified and n=15 non-calcified. *p,0.05, #p,0.06. f: fibrosa, v: ventricularis.
doi:10.1371/journal.pone.0020969.g005
Activation of SMAD1/5/8 on the Fibrosa Endothelium
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20969sistent with a previous report showing higher chordin mRNA ex-
pression on the ventricularis endothelium compared to the fibrosa
endothelium in normal porcine AV [20].
In addition to BMP antagonists, BMP pathway can be regulated
by inhibitory SMAD-6 and -7 [39]. This led us to test the alter-
native hypothesis that side-dependent activation of SMAD-1/5/8
and calcification is regulated by inhibitory SMAD-6. We found
that SMAD-6 expression levels were highest in the non-calcified
ventricularis endothelium, contributing to the anti-calcific envi-
ronment on the ventricularis-side of the AV (Fig. 5). Consistent
with our results, SMAD-6 was shown to be induced by laminar
shear stress in vascular endothelial cells [40]. Moreover, SMAD-6
deficiency causes cardiac valve hyperplasia in mice [41], demon-
strating its importance in AV biology.
Our results clearly show that the relative lack of the BMP
antagonists and inhibitory SMAD-6 in the fibrosa endothelium
correlates with the SMAD-1/5/8 phosphorylation in calcified
AVs; however, what is not clear is the mechanisms by which
SMAD-1/5/8 activation is prevented in non-calcified human AVs
compared to the calcified AVs.
There are several potential mechanisms that may explain this
finding. First, a recent study showed that patients with AV
calcification have significantly lower levels of circulating uncar-
boxylated MGP (ucMGP) than the healthy cohort [35]. They
suggested that the low level of ucMGP was due to the lack of
release of MGP into circulation. The deficiency in circulating
MGP, in combination with the lack of the BMP antagonists and
inhibitory SMAD-6 in the fibrosa endothelium, may promote the
side-dependent BMP pathway activation and calcification in
human AVs. Second, some BMP antagonists (e.g. follistatin,
chordin, MGP-1) that we could not examine due to the lack of
specific antibodies for immunostaining studies may also be res-
ponsible for our finding. Third, expression of the BMP receptors
may also contribute to the observed difference.
It is important to emphasize that the non-calcified AVs used for
this study were obtained from recipient hearts following heart
transplantations. Therefore, these samples were from heart failure
patients, not from a ‘‘healthy’’ subject population, and should not
be viewed as non-diseased AVs although they were not calcified.
The lack of healthy human aortic valve samples limited our ability
to study the factors that may be important in the initiation of this
disease. Since our study objective was to test the endothelial
expression levels of AV leaflets, we were limited in our approaches
to the immunohistochemical staining method since Western blots,
using endothelial lysates without significant interstitial contamina-
tion, could not be performed. This posed a quantitative and
mechanistic limitation in our study.
In summary, we showed that the BMP signaling pathway is
preferentially activated in the calcified fibrosa endothelium of
human AVs. This side- and disease-dependent activation of BMP
pathway correlates with the relative deficiency of the BMP
antagonists and inhibitory SMAD-6 in the fibrosa endothelium.
These findings suggest that preferential activation of BMP
pathways may be controlled by the balance between the BMPs
and BMP antagonists and that the BMP inhibitors play a
dominant role in side-dependent calcification of human AVs.
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